First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects

• Main Authors: Jing Yang (Author), Jason D. Lickliter (Author), Jan L. Hillson (Author), Gary D. Means (Author), Russell J. Sanderson (Author), Kay Carley (Author), Almudena Tercero (Author), Kristi L. Manjarrez (Author), Jennifer R. Wiley (Author), Stanford L. Peng (Author)
• Format: Book
• Published: Wiley, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the cluster of differentiation 28 (CD28) and inducible T cell costimulator (ICOS) pathways simultaneously. A first‐in‐human stud...